MX2012008222A - Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas. - Google Patents
Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas.Info
- Publication number
- MX2012008222A MX2012008222A MX2012008222A MX2012008222A MX2012008222A MX 2012008222 A MX2012008222 A MX 2012008222A MX 2012008222 A MX2012008222 A MX 2012008222A MX 2012008222 A MX2012008222 A MX 2012008222A MX 2012008222 A MX2012008222 A MX 2012008222A
- Authority
- MX
- Mexico
- Prior art keywords
- rtk
- methods
- receptor tyrosine
- inhibitors
- tyrosine kinases
- Prior art date
Links
- 102000027426 receptor tyrosine kinases Human genes 0.000 title abstract 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 title abstract 6
- 239000003112 inhibitor Substances 0.000 title 1
- 230000035578 autophosphorylation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33595010P | 2010-01-14 | 2010-01-14 | |
PCT/US2011/021109 WO2011088196A2 (en) | 2010-01-14 | 2011-01-13 | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012008222A true MX2012008222A (es) | 2012-08-17 |
Family
ID=44304965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012008222A MX2012008222A (es) | 2010-01-14 | 2011-01-13 | Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas. |
Country Status (14)
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2687896A1 (en) | 2007-06-05 | 2008-12-18 | Yale University | Antibody directed against the d4 ig-like domain of the kit receptor |
AR085091A1 (es) | 2011-01-26 | 2013-09-11 | Kolltan Pharmaceuticals Inc | Anticuerpos anti-kit y sus usos |
EP3381943B1 (en) | 2012-07-25 | 2022-03-16 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
JP2016506914A (ja) | 2013-01-16 | 2016-03-07 | アンセルムInserm | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
WO2014201034A2 (en) * | 2013-06-10 | 2014-12-18 | Ansun Biopharma, Inc. | Treatment for polyomavirus infection |
PT3708583T (pt) | 2013-08-01 | 2022-05-13 | Five Prime Therapeutics Inc | Anticorpos anti-fgfr2iiib afucosilados |
JO3515B1 (ar) | 2013-10-18 | 2020-07-05 | Eisai R&D Man Co Ltd | مثبطات fgfr4 بيريميدين |
CN106659782B (zh) | 2014-05-23 | 2021-11-09 | 塞尔德克斯医疗公司 | 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体 |
WO2016168331A1 (en) | 2015-04-14 | 2016-10-20 | Eisai R&D Management Co., Ltd. | Crystalline fgfr4 inhibitor compound and uses thereof |
US11447553B2 (en) | 2015-11-23 | 2022-09-20 | Five Prime Therapeutics, Inc. | FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
EP3454898B1 (en) | 2016-05-10 | 2021-11-10 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
CN110283803B (zh) * | 2016-06-02 | 2021-08-03 | 天津科技大学 | 一种磷脂酶d及其制备磷脂酸、磷脂酰丝氨酸的方法 |
EP3481859B1 (en) | 2016-07-07 | 2022-04-13 | Pfizer Inc. | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
CN118416216A (zh) | 2017-05-16 | 2024-08-02 | 戊瑞治疗有限公司 | 癌症治疗中抗fgfr2抗体与化学治疗剂的组合 |
CA3189470A1 (en) | 2020-08-21 | 2022-02-24 | Yves SABBAGH | Fgfr3 antibodies and methods of use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8426396B2 (en) * | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
-
2011
- 2011-01-13 IN IN5017DEN2012 patent/IN2012DN05017A/en unknown
- 2011-01-13 BR BR112012016992A patent/BR112012016992A2/pt not_active IP Right Cessation
- 2011-01-13 CA CA2786276A patent/CA2786276A1/en not_active Abandoned
- 2011-01-13 RU RU2012134637/10A patent/RU2012134637A/ru not_active Application Discontinuation
- 2011-01-13 SG SG2012045803A patent/SG181850A1/en unknown
- 2011-01-13 KR KR1020127021221A patent/KR20120130758A/ko not_active Withdrawn
- 2011-01-13 MX MX2012008222A patent/MX2012008222A/es not_active Application Discontinuation
- 2011-01-13 WO PCT/US2011/021109 patent/WO2011088196A2/en active Application Filing
- 2011-01-13 US US13/519,837 patent/US20120328599A1/en not_active Abandoned
- 2011-01-13 JP JP2012549070A patent/JP2013517282A/ja not_active Withdrawn
- 2011-01-13 CN CN2011800061813A patent/CN102762221A/zh active Pending
- 2011-01-13 EP EP11733365.8A patent/EP2523679A4/en not_active Withdrawn
- 2011-01-13 AU AU2011205297A patent/AU2011205297A1/en not_active Abandoned
-
2012
- 2012-06-06 IL IL220206A patent/IL220206A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2523679A2 (en) | 2012-11-21 |
SG181850A1 (en) | 2012-08-30 |
US20120328599A1 (en) | 2012-12-27 |
BR112012016992A2 (pt) | 2019-09-24 |
KR20120130758A (ko) | 2012-12-03 |
IN2012DN05017A (enrdf_load_stackoverflow) | 2015-10-02 |
WO2011088196A2 (en) | 2011-07-21 |
JP2013517282A (ja) | 2013-05-16 |
CN102762221A (zh) | 2012-10-31 |
IL220206A0 (en) | 2012-07-31 |
EP2523679A4 (en) | 2013-07-24 |
RU2012134637A (ru) | 2014-02-20 |
WO2011088196A3 (en) | 2011-11-17 |
CA2786276A1 (en) | 2011-07-21 |
AU2011205297A1 (en) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012008222A (es) | Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas. | |
PH12014500372A1 (en) | Compounds and compositions as c-kit kinase inhibitors | |
TN2014000061A1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
MX2014002486A (es) | Compuestos y composiciones como inhibidores de cinasa pdgfr. | |
WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
IL236495A0 (en) | Heteroaromatic compounds as proton tyrosine kinase inhibitors | |
HK1202377A1 (en) | Modulating certain tyrosine kinases | |
MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
EA201100425A1 (ru) | Производные пиколинамида в качестве ингибиторов киназы | |
EA201791133A1 (ru) | Ингибиторы erk | |
MX368707B (es) | Compuestos para usarse para inhibir c-kit cinasa fosforilada constitutivamente activa. | |
HK1204995A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
MX389105B (es) | Inhibidor de quinasas reordenadas durante la transfeccion (ret). | |
WO2011090738A3 (en) | Type ii raf kinase inhibitors | |
HUE061909T2 (hu) | Pirazolo[1,5-a]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére | |
MX2011009568A (es) | Inhibidores de la rho cinasa. | |
PH12012501581A1 (en) | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors | |
UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
ES2608829T8 (es) | Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida | |
EP2670244A4 (en) | BICYCLIC AND TRICYCLIC PYRIMIDINYROSINE KINASE INHIBITORS WITH ANTITUBULIN EFFECT AND METHOD FOR THE TREATMENT OF A PATIENT | |
EP2931281A4 (en) | AMINOPYRIDE-CONTAINING MILK TYROSINE KINASE HEMMER | |
MX344302B (es) | Compuestos de quinazolina sustituidos con alquino y metodos uso. | |
MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
MX2014009277A (es) | Antagonistas alk1 y sus usos en el tratamiento de carcinoma de celula renal. | |
EP2833886A4 (en) | SUBSTITUTED QUINOLINES AS INHIBITORS OF BRUTON TYROSINE KINASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |